全文获取类型
收费全文 | 4426篇 |
免费 | 247篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 100篇 |
妇产科学 | 58篇 |
基础医学 | 603篇 |
口腔科学 | 109篇 |
临床医学 | 522篇 |
内科学 | 840篇 |
皮肤病学 | 37篇 |
神经病学 | 352篇 |
特种医学 | 210篇 |
外科学 | 812篇 |
综合类 | 82篇 |
一般理论 | 2篇 |
预防医学 | 278篇 |
眼科学 | 84篇 |
药学 | 348篇 |
中国医学 | 11篇 |
肿瘤学 | 240篇 |
出版年
2022年 | 37篇 |
2021年 | 63篇 |
2019年 | 45篇 |
2018年 | 64篇 |
2017年 | 45篇 |
2016年 | 58篇 |
2015年 | 76篇 |
2014年 | 105篇 |
2013年 | 169篇 |
2012年 | 206篇 |
2011年 | 199篇 |
2010年 | 112篇 |
2009年 | 127篇 |
2008年 | 181篇 |
2007年 | 223篇 |
2006年 | 193篇 |
2005年 | 233篇 |
2004年 | 190篇 |
2003年 | 168篇 |
2002年 | 163篇 |
2001年 | 168篇 |
2000年 | 145篇 |
1999年 | 141篇 |
1998年 | 60篇 |
1997年 | 55篇 |
1996年 | 37篇 |
1995年 | 45篇 |
1993年 | 29篇 |
1992年 | 103篇 |
1991年 | 81篇 |
1990年 | 83篇 |
1989年 | 82篇 |
1988年 | 75篇 |
1987年 | 76篇 |
1986年 | 52篇 |
1985年 | 68篇 |
1984年 | 52篇 |
1983年 | 34篇 |
1982年 | 37篇 |
1981年 | 37篇 |
1980年 | 37篇 |
1979年 | 39篇 |
1978年 | 36篇 |
1976年 | 35篇 |
1975年 | 31篇 |
1974年 | 32篇 |
1973年 | 33篇 |
1972年 | 31篇 |
1971年 | 36篇 |
1970年 | 28篇 |
排序方式: 共有4755条查询结果,搜索用时 15 毫秒
1.
2.
Antimurine antibody formation following OKT3 therapy 总被引:1,自引:0,他引:1
T J Schroeder M R First M E Mansour P E Hurtubise S Hariharan F C Ryckman R Munda D B Melvin I Penn W F Ballistreri 《Transplantation》1990,49(1):48-51
OKT3 is an IgG2a murine monoclonal antibody directed against the CD3 antigen receptor of human T lymphocytes. A major concern with OKT3 treatment in solid organ transplant recipients is the development of antimouse antibody, which may preclude retreatment with this agent. We have administered OKT3 on 215 occasions (150 renal, 34 hepatic, 26 cardiac, 5 pancreatic) in 179 patients between April 1982 and December 1988. The mean duration of treatment was 10.5 days (range, 2-22 days). Antimouse antibody data were analyzed on the most recent 133 treatment courses where the antibody status was available pretreatment. Determination of antimouse antibody production was elicited by ELISA technology at days 0, 7, 14, and 28 of OKT3 treatment. Patients were categorized according to the antibody response as follows: (a) absence of antibody; (b) low titer (1:100); or (c) high titer (greater than or equal to 1:1000). Our earlier experience has demonstrated that retreatment with OKT3 is successful in groups a and b. The development of antimurine antibodies was analyzed with regard to the following parameters: (1) The duration of OKT3 treatment; (2) treatment type (prophylactic, primary, or secondary); (3) primary treatment or retreatment; (4) concomitant immunosuppressive regimen (double or triple therapy); (5) dosage of concomitant immunosuppressive drugs; and (6) transplant organ type. The following results were obtained. (1) Duration of treatment had no effect on antibody production (11.0 days in antibody negative and 10.0 days in antibody positive). (2) There was no difference in antibody formation rates for the first treatment of OKT3 when it was used as prophylaxis (26%), primary (19%), or secondary (27%) therapy. (3) Antibody formation rate with first treatment was 29%; with retreatment, patients who were antibody negative following first treatment became positive in 28% of cases, and retreated patients who were low titer positive following first treatment converted to high titer in 57% of cases. (4) Antibody formation was higher in patients receiving double immunosuppressive therapy (36%) than in those receiving triple immunosuppressive therapy (21%) during OKT3 treatment. (5) Concomitant immunosuppression was lower in the antibody-positive group during OKT3 therapy: steroids, 61 mg/day vs. 52 mg/day; azathioprine, 89 mg/day vs. 66 mg/day; CsA, 317 mg/day vs. 186 mg/day. (6) Antibody formation rates were lower in non-renal transplants following first treatment with OKT3 (liver 17%, heart 17%, kidney 28%); this reflects the higher doses of concomitant immunosuppressive therapy used in nonrenal transplants.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
3.
Immunohistochemical investigation of biopsies in a successful small-bowel transplantation 总被引:2,自引:0,他引:2
M L Hansmann K Hell M Gundlach E Deltz P Schroeder 《Transplantation proceedings》1990,22(6):2502-2503
4.
5.
6.
7.
The dose/effect relationships for intracameral doses of aceclidine HCl and pilocarpine HCl on total facility of outflow and accommodative amplitude were compared in the cynomolgus monkey eye in vivo. The largest dose of aceclidine tested (20 micrograms), resulted in an average increase of 270% in outflow facility, whereas accommodation was limited to an average of 5 diopters. In contrast, 20 micrograms of intracameral pilocarpine (which is submaximal in increasing facility) resulted in an average of 19 diopters of accommodation. These results provide further evidence for a dissociation between the accommodative and outflow facility functions of the ciliary muscle. 相似文献
8.
9.
W E Berdel S de Vos J Maurer D Oberberg Z von Marschall J K Schroeder J Li W D Ludwig E D Kreuser E Thiel 《Cancer research》1992,52(12):3498-3502
The growth of a panel of eight different human glioblastoma cell lines was examined in a human tumor cloning assay in agar, a tritiated thymidine uptake assay, and by counting cell numbers, in cultures performed in the absence or presence of increasing concentrations (1 to 100 ng/ml) of recombinant human stem cell factor (SCF). Growth of 7 of 8 cell lines was not significantly and reproducibly affected by recombinant human SCF. However, growth of the CRL 1620 cell line could be stimulated up to 5-fold by the cytokine. In contrast to the other cell lines investigated, CRL 1620 expressed the c-kit protooncogene assessed on the mRNA and protein level. Furthermore, SCF-induced proliferation of CRL 1620 cells was sensitive to the tyrosine kinase inhibitor erbstatin. Our data suggest that SCF can be operative in growth modulation of malignant cells outside the hematopoietic system, and this finding should be further studied for its possible clinical implications. 相似文献
10.